Combined Active Treatment in Type 2 Diabetes With NASH
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.
Also called NCT04639414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 192 participants
- Sponsor
- Registry
-
NCT04639414 -
2019-001987-31
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Germany
- Registry status
- Completed
Technical summary
Registry record NCT04639414. Randomized; triple masking; primary purpose treatment. Start 2021-03-26 (actual); primary completion 2025-01-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combined Active Treatment in Type 2 Diabetes With NASH
- Acronym
- COMBAT_T2_NASH
- Condition
- Type 2 Diabetes
- Condition
- Non-alcoholic Steatohepatitis (NASH)
- Condition
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Intervention (Drug)
- Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- Intervention (Drug)
- Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
- Intervention (Drug)
- Placebo matching empagliflozin and placebo pen injector matching semaglutide
- Lead sponsor
- German Diabetes Center
- Collaborator
- Boehringer Ingelheim
- Collaborator
- German Center for Diabetes Research
- Collaborator
- Federal Ministry of Health, Germany
- Collaborator
- Ministry of Innovation, Science and Research in North Rhine-Westphalia
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04639414- Content hash
5832a8ed5424d42066e5dfe0ebbdb6c23b1823ebb2838b3a125eef1673a9526b